Sign In  |  Register  |  About Corte Madera  |  Contact Us

Corte Madera, CA
September 01, 2020 10:27am
7-Day Forecast | Traffic
  • Search Hotels in Corte Madera

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

Texans’ Dylan Horton reveals stage 4 cancer diagnosis, says he’s now in remission

Houston Texans defensive end Dylan Horton announced in a statement Monday that he was diagnosed with Stage 4 Hodgkin’s Lymphoma in December and is now in remission.

Dylan Horton’s rookie season came to an abrupt end when the Houston Texans defensive end announced in November that he would be taking an indefinite leave of absence from the team to attend to a "personal health matter." 

On Monday, Horton revealed that he had been diagnosed with Stage 4 Hodgkin’s Lymphoma.

CLICK HERE FOR MORE SPORTS COVERAGE ON FOXNEWS.COM

But the second-year player also shared the good news that he is now in remission. 

"On December 1st, 2023, I was diagnosed with Stage 4 Hodgkin's Lymphoma. Through God’s grace, I’m blessed to say that I’m currently in remission," Horton said in a statement released by the team. 

JASON KELCE GIVES TRAINER TOUCHING GESTURE AT RETIREMENT CONFERENCE AFTER CANCER KEPT HIM FROM HIS FINAL GAME

"I am grateful for the love from my family and friends, and support from the Texans organization and my doctor," he continued. "My next objective is to complete my treatments, then get back to playing the game that I love. Thank you for your prayers and support as I continue this journey." 

A fourth-round pick out of TCU, Horton appeared in 10 games for the Texans, registering 13 tackles. He also recovered a fumble and recorded two quarterback hits.

Follow Fox News Digital’s sports coverage on X, and subscribe to the Fox News Sports Huddle newsletter.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Copyright © 2010-2020 CorteMadera.com & California Media Partners, LLC. All rights reserved.